Exovir Inc said the EuropeanPatent Office notified it that its application coveringcombinations of nonionic surfactants and all forms ofinterferon has been approved and a patent will be issued inabout six months.    Exovir is completing trials of a gel combining alphainterferon and nonoxynol-9, an antiviral surfactant, as atreatment for genital and oral herpes and genital warts. Thegel was given a U.S. patent in 1985.    It said clinical tests will begin shortly to test whetherthe gel is effective in preventing transmission of the AIDSvirus when used with a condom. Reuter&#3;